Here are the DEF 14A proxy statements from Lakewood-Amedex Biotherapeutics Inc. (LABT) in our archive over the last 12 months, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A DEF 14A covers the proxy statement, with executive pay and the shareholder votes, so if you follow LABT and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full LABT filings page.
Lakewood-Amedex Biotherapeutics Inc. is asking stockholders to approve several key actions at its September 22, 2026 virtual annual meeting. Stockholders will elect four directors to one-year terms; the slate includes CEO Kelvin Cooper and three independent directors.
The company seeks to amend its articles to increase authorized common stock from 12,500,000 to 100,000,000 shares. As of July 30, 2026, 2,369,688 shares were outstanding, with additional shares reserved for options and warrants; after the increase, approximately 97,387,493 shares would be authorized but unissued. A second capital proposal would authorize the board, at its discretion through September 22, 2027, to implement one or more reverse stock splits up to 1-for-20 to support Nasdaq Capital Market listing and potential financing flexibility.
The company also seeks to expand its 2020 Equity Incentive Plan from 183,505 to 400,000 shares to support employee and director equity awards. CBIZ CPAs P.C. is proposed for ratification as auditor; audit fees were $197,930 for 2025 and $107,427 for 2024. Executive agreements provide base salaries that step up after at least $5 million in private placement financing, immediate-vesting options at $0.39 per share, and severance of up to 18 months of salary upon certain terminations tied to a change in control.